ASCEND Study of Natalizumab Efficacy on Disability in Patients with Secondary Progressive Multiple Sclerosis (SPMS): Baseline Demographics and Disease Characteristics

被引：0
|
作者：
Mikol, Daniel
Freedman, Mark S.
Goldman, Myla D.
Hartung, Hans-Peter
Havrdova, Eva
Jeffery, Douglas
Kapoor, Raj
Miller, Aaron
Sellebjerg, Finn
Lee, Sophia
Chen, Yun
Cadavid, Diego
Ticho, Barry
机构：
来源：
ANNALS OF NEUROLOGY | 2013年 / 74卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S59 / S60
页数：2
相关论文
共 50 条
  • [31] Analyses of the effect of baseline age on the efficacy and safety of siponimod in patients with active secondary progressive multiple sclerosis from the EXPAND study
    Hua, L. H.
    Bar-Or, A.
    Lublin, F. D.
    Meng, X.
    Cox, G. M.
    Cree, B. Ac
    Fox, R. J.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 551 - 552
  • [32] Return of clinical and radiological disease activity after cessation of natalizumab in patients with relapsing remitting and secondary progressive multiple sclerosis
    Proschmann, U.
    Thomas, K.
    Ziemssen, T.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 319 - 320
  • [33] Baseline characteristics of amasia: first real world data of siponimod treated patients with secondary progressive multiple sclerosis
    Weber, M.
    Klotz, L.
    Schreiber, H.
    Rauser, B.
    Ziemssen, T.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 518 - 518
  • [34] Patient-reported physical functioning in relapsing-remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS) patients in Europe
    Jones, E.
    Naoshy, S.
    Pike, J.
    Watson, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 754 - 754
  • [35] Conversion to Non-Active Secondary Progressive Multiple Sclerosis (SPMS) in Patients Who Discontinued or Remained on Natalizumab in the Real-World TYSABRI Observational Program (TOP)
    Kappos, Ludwig
    Butkueven, Helmut
    Trojano, Maria
    Wiendl, Heinz
    Spelman, Tim
    Liao, Shirley
    Licata, Stephanie
    Drenth, Annemarie
    NEUROLOGY, 2021, 96 (15)
  • [36] Healthcare professionals (HCPS) categorisation of active and non-active secondary progressive multiple sclerosis (SPMS) patients
    White, J.
    Teoh, S.
    Gabriele, S.
    Vindici, J.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 243 - 244
  • [37] THE EVALUATION OF WORK PRODUCTIVITY IN RELAPSING-REMITTING (RRMS) AND SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS) PATIENTS IN EUROPE
    Pike, J.
    Naoshy, S.
    Watson, C.
    Jones, E.
    VALUE IN HEALTH, 2015, 18 (03) : A289 - A289
  • [38] The EXPAND study results: Efficacy of siponimod in secondary progressive multiple sclerosis
    Vermersch, P.
    Bar-Or, A.
    Cree, B.
    Fox, R.
    Giovannoni, G.
    Gold, R.
    Arnould, S.
    Wallstroem, E.
    Sidorenko, T.
    Wolf, C.
    Dahlke, F.
    Kappos, L.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 44 - 44
  • [39] Visual Evoked Potentials measure and correlation with disability progression (EDSS) in Relapsing-Remitting (RRMS) and Secondary Progressive Multiple Sclerosis (SPMS)
    Piccolo, A. C.
    Andrade, H. M. T.
    Brucki, S. M. D.
    Rocha, M. S. G.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (12) : 1872 - 1872
  • [40] The Pharmacokinetics of Lipoic Acid at Baseline and 48 Weeks in Secondary Progressive Multiple Sclerosis Patients
    Bittner, Frank
    Murchison, Charles
    Bourdette, Dennis
    Spain, Rebecca
    ANNALS OF NEUROLOGY, 2016, 80 : S117 - S117
12345